Bailie G R, Plitnick R, Eisele G, Clement C, Rasmussen R
Albany College of Pharmacy, New York.
Adv Perit Dial. 1991;7:292-5.
Experience in the use of subcutaneous erythropoietin in 18 CAPD patients is presented. The total and mean (SD) durations on CAPD were 419 and 23.3 (20.5) months, respectively. Eleven patients started treatment with normal or elevated iron stores, 7 had an initial iron saturation less than 20%. The initial hematocrit was 22.0 (3.1%). Eleven patients reached a steady state hematocrit (34.1 +/- 3.5%) by the end of the study period, and the mean percentage increase in hematocrit for all 18 patients was 47% over the initial hematocrit. All patients responded to EPO. The initial dose of EPO was 157.6 U/kg/wk, and all patients received oral iron supplements. There was no significant change in the means of any iron parameters. Transfusion requirements decreased from a mean of 0.42 transfusions per month per patient during the 12 months, prior to EPO, to 0.22 during the study. There were no significant changes in blood pressure or other measured parameters. Transient pain at the site of injection was noted infrequently.
本文介绍了18例持续性非卧床腹膜透析（CAPD）患者使用皮下促红细胞生成素的经验。患者接受CAPD治疗的总时长和平均（标准差）时长分别为419个月和23.3（20.5）个月。11例患者开始治疗时铁储备正常或升高，7例患者初始铁饱和度低于20%。初始血细胞比容为22.0（3.1%）。11例患者在研究期末达到稳定状态的血细胞比容（34.1±3.5%），18例患者血细胞比容相对于初始值的平均增幅为47%。所有患者对促红细胞生成素（EPO）均有反应。EPO初始剂量为157.6 U/kg/周，所有患者均接受口服铁补充剂治疗。各项铁参数均值无显著变化。输血需求从EPO治疗前12个月的平均每月每位患者0.42次输血，降至研究期间的0.22次。血压或其他测量参数无显著变化。注射部位偶尔出现短暂疼痛。
